Cardiovascular Toxicology

, Volume 7, Issue 2, pp 72-74

First online:

Cardiac safety of liposomal anthracyclines

  • Gerald BatistAffiliated withThe Montreal Center for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, The Sir Mortimer B Davis-Jewish General Hospital, McGill University Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Anthracyclines remain amongst the most active therapeutic agents for breast cancer treatment. Rather than being supplanted by novel targeted agents, they are being combined with them in various schedules. Furthermore, anthracyclines themselves are still being studied, with increasing biological understanding of their biological activity and molecular targets. A cardiac safe formulation of doxorubicin opens a number of interesting therapeutic opportunities. Liposomal doxorubicins appear to provide this opportunity.


Myocet Pegylated liposomal doxorubicin Trastuzumab Cardiotoxicity